clinical trial · NCT05166382
Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications
University of Colorado, Denver·N/A·completed·n = 350
Type 2 DiabetesCardiovascular DiseasesInformed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
brief summary
The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.
started
Jan 1, 2022
primary completion
Jan 1, 2024
completion
Jan 1, 2024
last updated
Mar 20, 2025
official title
Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications: An Adaptive Implementation Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol